ractigen - Ractigen Therapeutics - Page 2

Company News RAG-01

Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01

JIANGSU, China, Dec. 06, 2023 — Ractigen Therapeutics, a leader in the field of small…

ractigenDecember 6, 2023

Company News

Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS

Study aims to evaluate the safety and feasibility of RAG-17 in human patients and clinically…

ractigenJune 10, 2023

News Highlight

Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Jiangsu, China — Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA)…

ractigenMarch 3, 2023

© 2025 Ractigen Therapeutics. All Rights Reserved. Privacy Policy Terms